Fund Management

Dr. Campbell Murray

is a Managing Director in Cambridge, MA, USA.

Prior to joining Novartis Venture Fund, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician and worked as a Medical House Officer at Auckland Hospital. He is a Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio, BioNano Genomics, Euthymics, Galera, ImaginAb and Neurovance.


Exits: Akebia Therapeutics, Inc. (NASDAQ: AKBA), Alios BioPharma, Inc. (Acquired by J&J), Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI).  

Portfolio Companies

Annexon Neurosciences, Inc. (Board Seat)

BioNano Genomics, Inc. (Board Seat)

Euthymics Bioscience, Inc. (Board Seat)

Galera Therapeutics, Inc. (Board Seat)

ImaginAB, Inc. (Board Seat)

Neurovance, Inc. (Board Seat)

Aileron Therapeutics, Inc.